Moderna Cuts 2025 Forecast Amid Slow Vaccine Demand
Moderna, a biotech firm behind COVID-19 vaccines, cut its revenue forecast for 2025 by $1 billion due to weak demand for its newest vaccine and slow sales of its existing COVID-19 vaccine. The company now expects $1.5 billion to $2 billion in revenue. CEO Stéphane Bancel attributed the decline to a slower respiratory virus season, … Read more